Key Takeaway: Cognition Therapeutics has announced a significant finding regarding its drug's effectiveness in arresting cognitive decline in mild Alzheimer's patients. The reported figure indicates a 129% improvement in cognitive function. However, the article lacks detailed information about the study's methodology or results.
Price reaction · baseline $0.6478 (2025-07-30T16:28:00.000Z) · hit during market hours · clean, no other CGTX news in the window
day 0 close · peak
-4%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.